肺癌中的表皮生长因子受体外显子20插入突变和ERBB2突变：从口服激酶抑制剂到抗体药物共轭物的已获批准靶向疗法综述》勘误。

IF 4 2区医学 Q2 ONCOLOGY

Translational lung cancer research Pub Date : 2024-10-31 Epub Date: 2024-10-12 DOI:10.21037/tlcr-2024-1

引用次数: 0

摘要

[此处更正了文章 DOI：10.21037/tlcr-23-98]。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Erratum to EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates.

[This corrects the article DOI: 10.21037/tlcr-23-98.].

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Translational lung cancer research Medicine-Oncology

CiteScore

7.20

自引率

2.50%

发文量

137

期刊介绍： Translational Lung Cancer Research(TLCR, Transl Lung Cancer Res, Print ISSN 2218-6751; Online ISSN 2226-4477) is an international, peer-reviewed, open-access journal, which was founded in March 2012. TLCR is indexed by PubMed/PubMed Central and the Chemical Abstracts Service (CAS) Databases. It is published quarterly the first year, and published bimonthly since February 2013. It provides practical up-to-date information on prevention, early detection, diagnosis, and treatment of lung cancer. Specific areas of its interest include, but not limited to, multimodality therapy, markers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to lung cancer.